Resources

2 Resources for

agi therapeutics

Axcan and AGI Therapeutics Sign Exclusive License and Co-Development Agreement for the Next-Generation Therapy for GERD and the Control of Nocturnal Acid Breakthrough: Axcan Pharma Inc. (TSX: AXP)(NASDAQ: AXCA) today announced the signature of an exclusive license and co-development agreement with AGI Therapeutics, plc (AIM, IEX:AGI) for CHRONAB omeprazole ("AGI-010"). AGI-010 is a delayed/controlled release formulation of the proton pump inhibitor drug ("PPI") omeprazole and is being developed for the treatment of gastro-esophageal...; Tags: AGI Therapeutics, Axcan Pharma Inc.; Research articles 2006-09-26
Axcan and AGI Therapeutics Sign Exclusive License and Co-Development Agreement for the Next-Generation Therapy for GERD and the Control of Nocturnal Acid Breakthrough.: MONT-SAINT-HILAIRE, QUEBEC, Sep 26, 2006 CCNMatthews via COMTEX -- Axcan Pharma Inc. (TSX:AXP)(NASDAQ:AXCA) today announced the signature of an exclusive license and co-development agreement with AGI Therapeutics, plc (AIM, IEX:AGI) for CHRONAB omeprazole ("AGI-010"). AGI-010 is a delayed/controlled release formulation of the proton pump inhibitor...; Tags: AGI Therapeutics, Axcan Pharma Inc.; Research articles 2006-09-26

Market Alert for Tuesday! June 14, 2005.: M2 PRESSWIRE-14 June 2005-Wall Street News Alert: Market Alert for Tuesday! June 14, 2005C1994-2005 M2 COMMUNICATIONS LTD RDATE:14062005 Weston, FLA. - Wall Street News Alert's "stocks to watch" this morning are: WaveScribe International (OTC: WSBL), Cell Therapeutics, Inc. (NASDAQ: CTIC), Maxtor...; Tags: Fax, FINANCE, Investment, Nasdaq Stock Market Inc., NYSE Euronext, stock; Research articles 2005-06-14